Skip to main content
SpringerLink
Log in

Functions and relevance of the terminal complement sequence

  • Leading article
  • Published:
Blut Aims and scope Submit manuscript

Summary

The terminal complement sequence is initiated upon cleavage of C5 with liberation of C5a anaphylatoxin, and involves the assembly of macromolecular C5b—9 complexes either on cell surfaces or in plasma. Cell-bound C5b—9 complexes generate transmembrane pores that can cause cell death, or they can elicit secondary cellular reactions triggered, for example, by passive flux of calcium ions into the cells. In vivo functions of the fluid-phase SC5b—9 complex have not yet been defined, but the identity of S-protein with vitronectin (serum spreading factor) provokes the anticipation that significant biological functions of this complex do exist. The terminal complement sequence may fulfil protective functions when it is triggered on alien cells that are marked for destruction. Dysregulation in the complement sequence may, however, result in detrimental attack by C5b—9 on autologous cells. Examples include not only autoimmune disease states, but also the activation of complement on dead or dying cells, and bystander attack on blood cells during cardiopulmonary bypass. Methods for detecting and quantifying C5b—9 are outlined, and the potential usefulness of such assays in clinical research is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bariety J, Hinglais N, Bhakdi S, Mandet C, Rouchon M, Kazatchkine MD (1989) Immunohistochemical study of complement S-protein (vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b—9 terminal complex. Clin Exp Immunol 75: 76–81

    Google Scholar 

  2. Bhakdi S, Tranum-Jensen J (1985) Complement activation and attack on autologous cells induced by streptolysin-0. Infect Immun 48: 713–719

    Google Scholar 

  3. Bhakdi S, Tranum-Jensen J (1987) Damage to mammalian cells by proteins that form transmembrane pores. Rev Physiol Biochem Pharmacol 107: 147–223

    Google Scholar 

  4. Bhakdi S, Kuller G, Fromm S, Muhly M (1987) Formation of transmural complement pores in serum-sensitiveEscherichia coli. Infect Immun 55: 206–210

    Google Scholar 

  5. Bhakdi S, Fassbender W, Hugo F, Berstecher C, Malasit P, Kazatchkine MD (1988) Relative inefficiency of terminal complement activation. J Immunol 141: 3117–3122

    Google Scholar 

  6. Bhakdi S, Käflein R, Halstensen TS, Hugo F, Preissner KT, Mollnes TE (1988) Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b—9 complexes. Clin Exp Immunol 74: 459–464

    Google Scholar 

  7. Bhakdi S, Maillet F, Mahly M, Kazatchkine MD (1988) The cytolytic C5b—9 complement complex: feedback inhibition of complement activation. Proc Natl Acad Sci USA 85: 1912–1916

    Google Scholar 

  8. Campbell AK, Morgan BP (1985) Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack. Nature 317: 164–166

    Google Scholar 

  9. Carney DF, Hammer CH, Shin ML (1986) Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol 137: 263–270

    Google Scholar 

  10. Chenoweth DE, Hugli TE (1978) Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 75: 3943–3947

    Google Scholar 

  11. Couser WG, Baker PJ, Adler S (1985) Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Internat 28: 879–890

    Google Scholar 

  12. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H (1989) CD 59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170: 637–654

    Google Scholar 

  13. DiScipio RG (1987) Late-acting components of complement: their molecular biochemistry, role in the host defence, and involvement in pathology. Pathol Immunpathol Res 6: 343–370

    Google Scholar 

  14. Engel AG, Biesecker G (1982) Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol 12: 289–296

    Google Scholar 

  15. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A (1985) Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312: 1594–1599

    Google Scholar 

  16. Falk RJ, Podack E, Dalmasso AP, Jennette JC (1987) Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol 127: 182–190

    Google Scholar 

  17. Fosse E, Mollnes TE, Ingvaldsen B (1987) Complement activation during major operations with or without cardiopulmonary bypass. J Thor Cardiovasc Surg 93: 860–866

    Google Scholar 

  18. Halperin JA, Nicholson-Weller A, Brugnara C, Tosteson C (1988) Complement induces a transient increase in membrane permeability in unlysed erythrocytes. J Clin Invest 82: 594–600

    Google Scholar 

  19. Hänsch GM, Hammer CH, Vanguri P, Shin ML (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 78: 5118–5121

    Google Scholar 

  20. Hänsch GM, Seitz M, Martinotti G, Betz MM, Rauterberg EW, Gemsa D (1984) Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol 133: 2145–2150

    Google Scholar 

  21. Hildebrand A, Preissner KT, Müller-Berghaus G, Teschemacher H (1989) A novel β-endorphin binding protein. J Biol Chem 264: 15429–15434

    Google Scholar 

  22. Horigome I, Seino J, Sudo K, Kinoshita Y, Saito T (1987) Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Clin Exp Immunol 70: 417–424

    Google Scholar 

  23. Hügli T, Müller-Eberhard HJ (1978) Anaphylatoxins: C3a and C5a Adv Immunol 26: 1–55

    Google Scholar 

  24. Hugo F, Berstecher C, Krämer S, Fassbender W, Bhakdi S (1989) In vivo clearance studies of the terminal fluid-phase complement complex in rabbits. Clin Exp Immunol 77: 112–116

    Google Scholar 

  25. Hugo F, Krämer S, Bhakdi S (1987) Sensitive ELISA for quantitating the terminal membrane C5b—9 and fluid-phase SC5b—9 complex of human complement. J Immunol Meth 99: 243–251

    Google Scholar 

  26. Hummell DS, Winkelstein JA (1986) Bacterial lipoteichoic acid sensitizes host cells for destruction by autologous complement. J Clin Invest 77: 1533–1538

    Google Scholar 

  27. Imigawa DK, Osifchin NE, Paznekas WA, Shin ML, Mayer MM (1983) Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives. Proc Natl Acad Sci USA 80: 6647–6651

    Google Scholar 

  28. Jenne D, Stanley KK (1985) Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 4: 3153–3157

    Google Scholar 

  29. Joiner KA (1985) Studies on the mechanism of bacterial resistance to complement-mediated killing and on the mechanism of action of bactericidal antibody. Curr Top Microbiol Immunol 121: 99–133

    Google Scholar 

  30. Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH, Dourmashkin RR, Frank MM (1985) Multimeric complement component C9 is necessary for killing ofEscherichia coli J5 by terminal attack complex C5b—9. Proc Natl Acad Sci USA 82: 4808–4812

    Google Scholar 

  31. Kazatchkine MD, Nydegger UE (1982) The human alternative complement pathway. Prog Allergy 30: 193–222

    Google Scholar 

  32. Kazatchkine MD, Lambré CR, Kieffer N, Maillet F, Nurden AT (1984) Membrane-bound hemagglutinin mediates antibody and complement-dependent lysis of influenza virus-treated human platelets in autologous serum. J Clin Invest 74: 976–983

    Google Scholar 

  33. Kinoshita T, Takata Y, Kozono H, Takeda J, Hong K, Inoue K (1988) C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol 141: 3895–3901

    Google Scholar 

  34. Kirszbaum L, Sharpe JA, Murphy B, d'Apice AJF, Classon B, Hudson P, Walker ID (1990) Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J 8: 711–718

    Google Scholar 

  35. Kolb WP, Müller-Eberhard HJ (1975) Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci USA 72: 1687–1691

    Google Scholar 

  36. Kolb WP, Müller-Eberhard HJ (1975) The membrane attack mechanism of complement. Isolation and subunit composition of the C5b—9 complex. J Exp Med 141: 724–735

    Google Scholar 

  37. Koski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML (1983) Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci USA 80: 3816–3820

    Google Scholar 

  38. Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, Joiner KA (1987) Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies. J Clin Invest 80: 1492–1497

    Google Scholar 

  39. Medof ME, Walter EI, Roberts WL, Haas R, Rosenberry TL (1986) Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry 25: 6740–6747

    Google Scholar 

  40. Mollnes TE, Lea T, Froland SS, Harboe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand Immunol 22: 197–202

    Google Scholar 

  41. Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M (1986) Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthrit Rheumat 29: 715–721

    Google Scholar 

  42. Mollnes TE, Vandvik B, Lea T, Vartdal F (1987) Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 78: 17–28

    Google Scholar 

  43. Müller-Eberhard HJ (1988) Molecular organization and function of the complement system. Ann Rev Biochem 57: 321–347

    Google Scholar 

  44. Murphy BF, Kirszbaum L, Walker ID, d'Apice JF (1988) SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest 81: 1858–1864

    Google Scholar 

  45. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF (1983) Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein decay accelerating factor. Proc Natl Acad Sci USA 80: 5066–5070

    Google Scholar 

  46. Niculescu F, Rus HG, Vlaicu R (1987) Immunohistochemical localization of C5b—9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65: 1–11

    Google Scholar 

  47. Preissner KT (1989) The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut 59: 419–431

    Google Scholar 

  48. Preissner KT, Müller-Berghaus G (1987) Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem 262: 12174–12253

    Google Scholar 

  49. Pytela R, Pierschbacher MD, Ruoslahti E (1985) A 125/115 kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 82: 5766–5770

    Google Scholar 

  50. Salama A, Mueller-Eckhardt C, Boschek B, Bhakdi S (1987) Haemolytic efficiency of C5b—9 complexes in drug-induced immune haemolysis: role of cellular C5b—9 distribution. Br J Haematol 65: 217–222

    Google Scholar 

  51. Salama A, Hugo F, Heinrich D, Höge R, Müller R, Kiefel V, Mueller-Eckhardt C, Bhakdi S (1988) Deposition of terminal C5b—9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 318: 408–413

    Google Scholar 

  52. Sanders M, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA (1986) Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. J Immunol 136: 4456–4459

    Google Scholar 

  53. Schäfer H, Mathey D, Hugo F, Bhakdi S (1986) Deposition of the terminal C5b—9 complement complex in infarcted areas of human myocardium. J Immunol 137: 1945–1949

    Google Scholar 

  54. Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136: 1772–1776

    Google Scholar 

  55. Seeger W, Suttorp N, Hellwig A, Bhakdi S (1986) Non-cytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol 137: 1286–1291

    Google Scholar 

  56. Seeger W, Hartmann R, Neuhoff H, Bhakdi S (1989) Local complement activation, thromboxane-mediated vasoconstriction, and vascular leakage in isolated lungs. Role of the terminal complement sequence. Am Rev Resp Dis 139: 88–99

    Google Scholar 

  57. Seifert PS, Hugo F, Hansson GK, Bhakdi S (1989) Prelesional complement activation in experimental atherosclerosis. Lab Invest 60: 747–754

    Google Scholar 

  58. Sugita Y, Nakano Y, Tomita M (1988) Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement channels. J Biochem 104: 632–637

    Google Scholar 

  59. Suttorp N, Seeger W, Zinsky S, Bhakdi S (1987) Complement complex C5b—8 induces PGI2 formation in cultured endothelial cells. Am J Physiol 253: C13-C21

    Google Scholar 

  60. Suttorp N, Hessz T, Seeger W, Wilke A, Koob R, Lutz F, Drenckhahn D (1988) Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol 255: C368-C376

    Google Scholar 

  61. Thompson RA, Lachmann PJ (1970) Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med 131: 629–643

    Google Scholar 

  62. Vaara M, Vaara T (1983) Sensitization of Gram-negative bacteria to antibiotics and complement by a non-toxic oligopeptide. Nature 303: 526–528

    Google Scholar 

  63. Wiedmer T, Esmon CR, Sims PJ (1986) On the mechanism by which complement proteins C5b—9 increase platelet prothrombinase activity. J Biol Chem 261: 14587–14592

    Google Scholar 

  64. Wright SD, Levine RP (1981) How complement kills.E. coli. I. Location of the lethal lesion. J Immunol 127: 1146–1151

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Microbiology, University of Giessen, D-6300, Giessen, Federal Republic of Germany

    Sucharit Bhakdi & Ferdinand Hugo

  2. Anatomy Institute C, University of Copenhagen, Panum Institute, DK-2200, Copenhagen N, Denmark

    Jorgen Tranum-Jensen

Authors
  1. Sucharit Bhakdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferdinand Hugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorgen Tranum-Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhakdi, S., Hugo, F. & Tranum-Jensen, J. Functions and relevance of the terminal complement sequence. Blut 60, 309–318 (1990). https://doi.org/10.1007/BF01737843

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01737843

Key words

Search

Navigation